The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
The company is making a high-risk, high-reward bet with the purchase of Gyroscope.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.